Duvakitug

Phase 3Small molecule

Sanofi

Duvakitug is one of 80 small molecule programs targeting Crohn's Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Crohn's DiseaseRecruiting

Ulcerative ColitisActive, not recruiting

Crohn's DiseasePhase 3

Recruiting

Ulcerative ColitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Adtralza

LEO Pharma

Phase 3

1 2

JNJ-42756493

SC Golimumab

1 4

IV Golimumab

Merck & Co.

Phase 3

1 5

TA-650

Tanabe Pharma Corporation

Phase 3

1 6

Budesonide MMX

Ferring

Phase 3

4 7

Propionyl-L-Carnitine

LLee's Pharmaceutical Limited

Phase 3

3 8

Simponi

Johnson & Johnson

Preclinical

15 9

Duvakitug

Sanofi

Phase 3

2 10

CT-P13 SC (infliximab)

CCelltrion

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Ulcerative Colitis

NCT07184996

Q2 2029

Phase 3Recruiting

Crohn's Disease

NCT07184931

Q2 2033

Phase 3Recruiting

Ulcerative Colitis

NCT07185009

Q1 2034

Phase 3Recruiting

Crohn's Disease

NCT07184944

Clinical

Trials by Indication[1]

Ulcerative Colitis2 trials

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07184996·980 enrolled

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07185009·671 enrolled

Crohn's Disease2 trials

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07184931·980 enrolled

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07184944·751 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Duvakitug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Duvakitug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Duvakitug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Duvakitug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2029

Q2 2033

Q1 2034

Trials by Indication[1]

Ulcerative Colitis2 trials

Crohn's Disease2 trials

References

Drug Info

Quick Facts

Related News